Al Sandrock On His First Mission At Voyager: Cracking The Tau Alzheimer’s Puzzle
Ex-Biogen Research Head Prioritizes Anti-Tau Antibody
Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.
You may also be interested in...
Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.
Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.